14th International Child Neurology Congress
RAI Amsterdam *Amsterdam, NETHERLANDS Visit the Venue to read more
It is with great pleasure that we invite you to attend the 14th International Child Neurology Congress from May 1st – 5th, 2016 in Amsterdam, the Netherlands.
The theme of ICNC 2016 will be:
“Bridging Worlds; Child Neurology from a Global Perspective”.
The congress will reach and unite professionals in pediatric neurology from all over the world by offering a program that is of global relevance and has a significant educational impact, and by facilitating participation of delegates from all countries.
With our innovative program format, we will offer:
complimentary breakfast teaching sessions
afternoon meet-the-expert interactive tutorial sessions
free evening masterclasses
four morning parallel sessions, that will each include 3 lectures given by experts in the field, covering current state-of-the-art, controversies or consensus, and expected developments
each day, one of these parallel sessions will be specifically devoted to differences in diagnostics and treatment of pediatric neurological disorders across the world
four afternoon platform sessions that start with an introductory lecture given by an experienced chair
lunch symposia on specific child neurology topics, selected from submitted session proposals
25 travel bursaries, as well as significantly reduced registration fees, for participants from low-resource countries.
The 2016 ICNC meeting will be held at the Amsterdam RAI Convention Center, a modern venue that is within ten minutes reach of Schiphol Amsterdam Airport, providing direct connections with most continents and many countries (100 non-stop intercontinental and 300 direct European destinations). The venue is close to the heart of historical Amsterdam. Thousands of hotel rooms in all possible price categories, ranging from luxury hotel chains to low-budget accommodation, are available within walking distance from the conference venue.
We kindly invite you all to submit proposals for lunch symposia (further information available on www.icnc2016.org, website open from May 1st) and abstracts (online submission open from June 1st).
Please mark your calendar! We look forward to welcoming you all in the beautiful city of Amsterdam, during the season of tulips, for the 14th ICNC from May 1st to 5th 2016.
On behalf of the organizing, scientific and educational committee, and the Dutch Society of Pediatric Neurology,
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
Amsterdam The Netherlands
The 14th International Child Neurology Congress aims to cover all aspects of child neurology and affiliated topics. You are invited to submit abstracts on the following topics. Submissions will be considered for platform and poster presentations. All abstracts are to be submitted online and should be a maximum of 250 words. See detailed author guidelines below
Submissions Open June 1, 2015
Submissions Close Dec 1, 2015
Topics (during abstract submission, you will be asked to select one of the below mentioned topics)
Ethics and history
Fetal and neonatal neurology
Intellectual disability and chromosomal disorders
Learning and behavioral disorders
Ophthalmology and otology
Stroke and vascular disorders
Traumatology and critical care
White matter disorders
On-line abstract submission is available here.
Abstracts are required for all papers and posters.
Abstracts MUST be submitted ONLINE
The above mentioned website will first require you to create a “profile”. With this profile you will be able to submit several abstracts, and log in to your submission page and view your submission
The abstract submission form will ask for the following information: Title of your abstract, abstract text (maximum 250 words), abstract topics, presentation preference (platform or poster presentation), the names and affiliations of all authors
In case you have any questions, please contact the congress secretariat at email@example.com or +31205040200.
Preparation of your abstract
A “blind” peer review process will be used. No identifying features such as names of hospitals, medical schools, universities, clinics or cities may be listed in the title or text of the abstract. Do not include the names of authors either. The names of authors and their affiliations (institutions) will be submitted on-line when you submit the abstract.
Abstracts which have been presented to a substantially different audience, especially a local or regional one, may be submitted for consideration.
Abstracts should state briefly and clearly an introduction, methods or description of the case results and discussion points. The maximum word count is 250 words.
Title: The title should be as brief as possible but long enough to indicate clearly the nature of the study.
Introduction: Describe the context of the research/case and explain its relevance and importance
Methods: Concise description of the process by which the research was conducted
Case Description (if applicable): Report the case using the standard medical sequence
Results: The results or outcome of your work. If you don’t have final results yet in time for the abstract submission, you can either include any preliminaryresults that you do have, or you can briefly mention the results that you expect to obtain. Abstracts without any mention of results or indicated “to be confirmed” will not be accepted.
Conclusion/Discussion: Discuss the reasons for particular decisions being made and highlight any important learning points or lessons.
Acknowledgements can be mentioned in the text of the abstract
Units and Symbols: Metric units according to the System of International Units (SI) should be used.
Equations should use the Equation style, tab centred with the number in parentheses on the right, as shown here: I = Ioe-x(1)
Abbreviations: Use standard abbreviations. For terms that are abbreviated, use the whole the first time, followed by the abbreviation in parenthesis. Abbreviate journal titles according to Index Medicus and give year, volume number and inclusive pages. Use references sparingly within the body of your abstract.
References: For journals, mention first author “et al” followed by the name of the journal as abbreviated in the Index Medicus, year, volume number and inclusive pages (i.e. Hardus P et al. Epilepsia 2001;42:262-267.). For book chapters, give first author “et al”, editor, title, publisher, city of publication, year and inclusive pages (i.e. Levy RH et al. In: Levy RH et al, Antiepileptic Drugs. Lippincott-Raven, 1996;13-30.)
International nonproprietary names and abbreviations for antiepileptic drugs as published in Epilepsia 1993; 34(6):1151, should be used. References for book chapters should consist of editor, title, city of publication, publisher, year and inclusive pages. Non-proprietary names of drugs must be used throughout. If results are considered to be specific for a given proprietary product (for example, bio-equivalence studies), the non-proprietary name must still be used, followed by the proprietary name and the name of the manufacturers in brackets.
Authors are advised that abstracts without an explicit concluding sentence stating the significance of the findings will not be accepted. It is not satisfactory to say the results will be discussed. Case reports are strongly discouraged unless they present very novel and significant findings or potential therapies, as determined by the ICNC Scientfic Program Review Committee. Please include hard data such as the “n” or “p” of observations and statistical values.
Acceptance emails will be sent out in February 2016. Authors are required to confirm their plan to present at the ICNC2016 upon receipt of the acceptance email. If the abstract is withdrawn for any reason prior to the meeting, authors are responsible for notifying the ICNC2016 secretariat immediately at firstname.lastname@example.org.
At least one author for each abstract that is accepted for presentation in the Conference Program is expected to register and pay to attend the Conference to present their research. All of the costs to attend the Conference, including the registration fee, must be paid by presenters
The ICNC 2016 organisation offers a wide range of sponsoring and exhibiting opportunities.
In order to receive more information and the sponsoring prospectus, please contact us at email@example.com
At Shire, we enable people with life-altering conditions to lead better lives. We focus on developing and delivering innovative medicines for patients with rare diseases and other specialty conditions. This might be a therapy to treat an extremely rare and life-threatening disease such as Hunter syndrome or Fabry disease, or a medicine for a specialist condition such as ADHD or ulcerative colitis.
To realize our aspiration to become a leading global biotech, our efforts are concentrated on four key strategic drivers: growth, innovation, efficiency, and people. Our priorities are to drive optimal performance of our existing products, increase patient access to these medicines, and to build our pipeline through research and development and partnerships in order to deliver new medicines to patients.
ICNA Contact Information
540 Judson Avenue, 60202-3084, Evanston IL, USA
Phone: (1 847) 475 7589